

Brian Salmons

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6936744/publications.pdf>

Version: 2024-02-01

127
papers

3,620
citations

136950

32
h-index

161849

54
g-index

132
all docs

132
docs citations

132
times ranked

2757
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficient protection of microorganisms for delivery to the intestinal tract by cellulose sulphate encapsulation. <i>Microbial Cell Factories</i> , 2020, 19, 216.	4.0	21
2	Semipermeable Cellulose Beads Allow Selective and Continuous Release of Small Extracellular Vesicles (sEV) From Encapsulated Cells. <i>Frontiers in Pharmacology</i> , 2020, 11, 679.	3.5	11
3	Use of cell therapy as a means of targeting chemotherapy to inoperable pancreatic cancer.. <i>Acta Biochimica Polonica</i> , 2019, 52, 601-607.	0.5	12
4	Commentary regarding Gannon et al. "Viral infections and breast cancer" A current perspective. <i>Cancer Letters</i> , 2018, 424, 117-118.	7.2	2
5	Editorial: IJDD Past and Future Progress. <i>International Journal of Developmental Disabilities</i> , 2018, 64, 1-2.	2.0	0
6	Non-clinical safety assessment of repeated intramuscular administration of an EV-A71 VLP vaccine in rabbits. <i>Vaccine</i> , 2018, 36, 6623-6630.	3.8	6
7	Release characteristics of cellulose sulphate capsules and production of cytokines from encapsulated cells. <i>International Journal of Pharmaceutics</i> , 2018, 548, 15-22.	5.2	13
8	Oncogenic Viruses and Breast Cancer: Mouse Mammary Tumor Virus (MMTV), Bovine Leukemia Virus (BLV), Human Papilloma Virus (HPV), and Epstein-Barr Virus (EBV). <i>Frontiers in Oncology</i> , 2018, 8, 1.	2.8	175
9	65 years and counting. <i>International Journal of Developmental Disabilities</i> , 2017, 63, 1-1.	2.0	0
10	Comment on Patel et al; "Protein transfer-mediated surface engineering to adjuvantate virus-like nanoparticles for enhanced anti-viral immune responses" <i>Nanomedicine</i> , 2015, 11(5): p. 1097-107. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2016, 12, 665-666.	3.3	2
11	Commentary: With a little help from my enteric microbial friends. <i>Frontiers in Microbiology</i> , 2015, 6, 1029.	3.5	1
12	Encapsulated Cells Expressing a Chemotherapeutic Activating Enzyme Allow the Targeting of Subtoxic Chemotherapy and Are Safe and Efficacious: Data from Two Clinical Trials in Pancreatic Cancer. <i>Pharmaceutics</i> , 2014, 6, 447-466.	4.5	24
13	New developments at the <i>International Journal of Developmental Disabilities</i> . <i>International Journal of Developmental Disabilities</i> , 2014, 60, 1-2.	2.0	0
14	Recent developments linking retroviruses to human breast cancer: infectious agent, enemy within or both?. <i>Journal of General Virology</i> , 2014, 95, 2589-2593.	2.9	22
15	Phase I/II Clinical Trial of Encapsulated, Cytochrome P450 Expressing Cells as Local Activators of Cyclophosphamide to Treat Spontaneous Canine Tumours. <i>PLoS ONE</i> , 2014, 9, e102061.	2.5	13
16	Revisiting a role for a mammary tumor retrovirus in human breast cancer. <i>International Journal of Cancer</i> , 2013, 133, 1530-1535.	5.1	27
17	The 5' leader sequence of mouse mammary tumor virus enhances expression of the envelope and reporter genes. <i>Journal of General Virology</i> , 2012, 93, 308-318.	2.9	7
18	Evaluation of a Gene-Directed Enzyme-Product Therapy (GDEPT) in Human Pancreatic Tumor Cells and Their Use as In Vivo Models for Pancreatic Cancer. <i>PLoS ONE</i> , 2012, 7, e40611.	2.5	12

#	ARTICLE	IF	CITATIONS
19	Comparative evaluation of preclinical in vivo models for the assessment of replicating retroviral vectors for the treatment of glioblastoma. <i>Journal of Neuro-Oncology</i> , 2011, 102, 59-69.	2.9	25
20	Mouse mammary tumor-like virus and human breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 907-909.	2.5	3
21	Mouse Mammary Tumor Virus-like Sequences in Human Breast Cancer. <i>Cancer Research</i> , 2010, 70, 3576-3585.	0.9	58
22	Therapeutic Application of Cell Microencapsulation in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2010, 670, 92-103.	1.6	15
23	Encapsulated cells to focus the metabolic activation of anticancer drugs. <i>Current Opinion in Molecular Therapeutics</i> , 2010, 12, 450-60.	2.8	12
24	Human Endogenous Retroviral Long Terminal Repeat Sequences as Cell Type-Specific Promoters in Retroviral Vectors. <i>Journal of Virology</i> , 2009, 83, 12643-12650.	3.4	22
25	Influence of vector design and host cell on the mechanism of recombination and emergence of mutant subpopulations of replicating retroviral vectors. <i>BMC Molecular Biology</i> , 2009, 10, 8.	3.0	6
26	Singapore R&D and globetrotting. <i>Biotechnology Journal</i> , 2009, 4, 179-185.	3.5	1
27	Small Agarose Microcapsules with Cell-Enclosing Hollow Core for Cell Therapy: Transplantation of Ifosfamide-Activating Cells to the Mice with Preestablished Subcutaneous Tumor. <i>Cell Transplantation</i> , 2009, 18, 933-939.	2.5	19
28	Stem cell therapies: on track but suffer setback. <i>Current Opinion in Molecular Therapeutics</i> , 2009, 11, 360-3.	2.8	10
29	Reconstituting retroviral (ReCon) vectors facilitating delivery of cytotoxic genes in cancer gene therapy approaches. <i>Journal of Gene Medicine</i> , 2008, 10, 113-122.	2.8	8
30	Rafts, anchors and viruses – A role for glycosylphosphatidylinositol anchored proteins in the modification of enveloped viruses and viral vectors. <i>Virology</i> , 2008, 382, 125-131.	2.4	38
31	Quantification and Characterization of Autotransduction in Retroviral Vector Producer Cells. <i>Human Gene Therapy</i> , 2008, 19, 97-102.	2.7	2
32	Identification of the Rem-responsive element of mouse mammary tumor virus. <i>Nucleic Acids Research</i> , 2008, 36, 6284-6294.	14.5	30
33	Association of glycosylphosphatidylinositol-anchored protein with retroviral particles. <i>FASEB Journal</i> , 2008, 22, 2734-2739.	0.5	27
34	Transgene Expression Facilitated by the v- <i>src</i> Splice Acceptor Can Impair Replication Kinetics and Lead to Genomic Instability of Rous Sarcoma Virus-Based Vectors. <i>Journal of Virology</i> , 2008, 82, 1610-1614.	3.4	1
35	Mouse Mammary Tumor Virus Integration Site Selection in Human and Mouse Genomes. <i>Journal of Virology</i> , 2008, 82, 1360-1367.	3.4	82
36	Mouse Mammary Tumor Virus Promoter-Containing Retroviral Promoter Conversion Vectors for Gene-Directed Enzyme Prodrug Therapy are Functional in Vitro and in Vivo. <i>Journal of Biomedicine and Biotechnology</i> , 2008, 2008, 1-10.	3.0	8

#	ARTICLE	IF	CITATIONS
37	Effects of Viral Strain, Transgene Position, and Target Cell Type on Replication Kinetics, Genomic Stability, and Transgene Expression of Replication-Competent Murine Leukemia Virus-Based Vectors. <i>Journal of Virology</i> , 2007, 81, 6973-6983.	3.4	15
38	Promoter Complex in the Central Part of the Mouse Mammary Tumor Virus Long Terminal Repeat. <i>Journal of Virology</i> , 2007, 81, 12572-12581.	3.4	4
39	Rapid spread of mouse mammary tumor virus in cultured human breast cells. <i>Retrovirology</i> , 2007, 4, 73.	2.0	56
40	Simian immunodeficiency virus vector pseudotypes differ in transduction efficiency and target cell specificity in brain. <i>Gene Therapy</i> , 2007, 14, 1330-1343.	4.5	20
41	Bacteriophage-encoded toxins: the ϕ -holin protein causes caspase-independent non-apoptotic cell death of eukaryotic cells. <i>Cellular Microbiology</i> , 2007, 9, 1753-1765.	2.1	15
42	Mutations in the catalytic core or the C-terminus of murine leukemia virus (MLV) integrase disrupt virion infectivity and exert diverse effects on reverse transcription. <i>Virology</i> , 2007, 362, 50-59.	2.4	12
43	GMP Production of an Encapsulated Cell Therapy Product: Issues and Considerations. <i>BioProcessing: Advances and Trends in Biological Product Development</i> , 2007, 6, 37-44.	0.1	9
44	WPRE-mediated enhancement of gene expression is promoter and cell line specific. <i>Gene</i> , 2006, 372, 153-161.	2.2	63
45	MMTV accessory factor Naf affects cellular gene expression. <i>Virology</i> , 2006, 346, 139-150.	2.4	3
46	Hypoxia- and radiation-inducible, breast cell-specific targeting of retroviral vectors. <i>Virology</i> , 2006, 349, 121-133.	2.4	9
47	Cytochrome P450 reductase dependent inhibition of cytochrome P450 2B1 activity: Implications for gene directed enzyme prodrug therapy. <i>Biochemical Pharmacology</i> , 2006, 72, 893-901.	4.4	12
48	Enhancement of the StreptoTag method for isolation of endogenously expressed proteins with complex RNA binding targets. <i>Electrophoresis</i> , 2006, 27, 1874-1877.	2.4	19
49	The cytotoxic activity of the bacteriophage ϕ -holin protein reduces tumour growth rates in mammary cancer cell xenograft models. <i>Journal of Gene Medicine</i> , 2006, 8, 229-241.	2.8	30
50	Tissue- and Tumor-Specific Targeting of Murine Leukemia Virus-Based Replication-Competent Retroviral Vectors. <i>Journal of Virology</i> , 2006, 80, 7070-7078.	3.4	18
51	FMDV α 2A sequence and protein arrangement contribute to functionality of CYP2B1 β reporter fusion protein. <i>Analytical Biochemistry</i> , 2005, 343, 116-124.	2.4	38
52	A novel, mouse mammary tumor virus encoded protein with Rev-like properties. <i>Virology</i> , 2005, 337, 1-6.	2.4	89
53	Effect of posttranscriptional regulatory elements on transgene expression and virus production in the context of retrovirus vectors. <i>Virology</i> , 2005, 341, 1-11.	2.4	26
54	Abundant authentic MMTV-Env production from a recombinant provirus lacking the major LTR promoter. <i>Virology</i> , 2005, 342, 201-214.	2.4	2

#	ARTICLE	IF	CITATIONS
55	A 470Åbp WAP-promoter fragment confers lactation independent, progesterone regulated mammary-specific gene expression in transgenic mice. <i>Transgenic Research</i> , 2005, 14, 145-158.	2.4	7
56	Mouse Mammary Tumor Virus Infects Human Cells. <i>Cancer Research</i> , 2005, 65, 6651-6659.	0.9	92
57	Subsieve-size agarose capsules enclosing ifosfamide-activating cells: a strategy toward chemotherapeutic targeting to tumors. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 1786-1790.	4.1	29
58	HIV-1 Rev can specifically interact with MMTV RNA and upregulate gene expression. <i>Gene</i> , 2005, 358, 17-30.	2.2	11
59	Combination Suicide Gene Therapy. , 2004, 90, 345-352.		2
60	Multiple Modifications Allow High-Titer Production of Retroviral Vectors Carrying Heterologous Regulatory Elements. <i>Journal of Virology</i> , 2004, 78, 1384-1392.	3.4	21
61	Effects of sequences of prokaryotic origin on titer and transgene expression in retroviral vectors. <i>Virology</i> , 2004, 330, 351-360.	2.4	13
62	Encapsulated, genetically modified cells producing in vivo therapeutics. <i>Current Opinion in Molecular Therapeutics</i> , 2004, 6, 412-20.	2.8	14
63	Intra-arterial instillation of microencapsulated, ifosfamide-activating cells in the pig pancreas for chemotherapeutic targeting. <i>Pancreatology</i> , 2003, 3, 55-63.	1.1	11
64	Treatment of inoperable pancreatic carcinoma using a cell-based local chemotherapy: results of a phase I/II clinical trial. <i>Journal of Gastroenterology</i> , 2003, 38 Suppl 15, 78-84.	5.1	20
65	Novel treatments and therapies in development for pancreatic cancer. <i>Expert Opinion on Investigational Drugs</i> , 2002, 11, 769-786.	4.1	21
66	[35] Microencapsulation of genetically engineered cells for cancer therapy. <i>Methods in Enzymology</i> , 2002, 346, 603-618.	1.0	14
67	Specific packaging of spliced retroviral vector transcripts lacking the ψ -region. <i>Biochemical and Biophysical Research Communications</i> , 2002, 293, 239-246.	2.1	20
68	Recipes for success?. <i>Trends in Molecular Medicine</i> , 2002, 8, 309.	6.7	1
69	Encapsulated cells producing retroviral vectors for in vivo gene transfer. <i>Journal of Gene Medicine</i> , 2002, 4, 150-160.	2.8	21
70	Microencapsulated, CYP2B1-transfected cells activating ifosfamide at the site of the tumor: the magic bullets of the 21st century. <i>Cancer Chemotherapy and Pharmacology</i> , 2002, 49, 21-24.	2.3	32
71	The murine whey acidic protein promoter directs expression to human mammary tumors after retroviral transduction. <i>Cancer Gene Therapy</i> , 2002, 9, 421-431.	4.6	18
72	JMM " Past and Present. <i>Journal of Molecular Medicine</i> , 2002, 80, 610-614.	3.9	9

#	ARTICLE	IF	CITATIONS
73	Encapsulated cells producing retroviral vectors for in vivo gene transfer. <i>Journal of Gene Medicine</i> , 2002, 4, 150-60.	2.8	5
74	Novel clinical strategies for the treatment of pancreatic carcinoma. <i>Trends in Molecular Medicine</i> , 2001, 7, 30-37.	6.7	36
75	Viruses: friend or foe?. <i>Trends in Molecular Medicine</i> , 2001, 7, 185.	6.7	0
76	Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. <i>Lancet</i> , The, 2001, 357, 1591-1592.	13.7	202
77	Influence of Preassay and Sequence Variations on Viral Load Determination by a Multiplex Real-Time Reverse Transcriptase-Polymerase Chain Reaction for Feline Immunodeficiency Virus. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2001, 26, 8-20.	2.1	57
78	Influence of Preassay and Sequence Variations on Viral Load Determination by a Multiplex Real-Time Reverse Transcriptase-Polymerase Chain Reaction for Feline Immunodeficiency Virus. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2001, 26, 8-20.	2.1	51
79	Genetic reshuffling reconstitutes functional expression cassettes in retroviral vectors. <i>Journal of Gene Medicine</i> , 2001, 3, 418-426.	2.8	6
80	Necrotic, rather than apoptotic, cell death caused by cytochrome P450-activated ifosfamide. <i>Cancer Gene Therapy</i> , 2001, 8, 220-230.	4.6	35
81	Combined chemotherapy of murine mammary tumors by local activation of the prodrugs ifosfamide and 5-fluorocytosine. <i>Cancer Gene Therapy</i> , 2000, 7, 629-636.	4.6	29
82	Accurate estimation of transduction efficiency necessitates a multiplex real-time PCR. <i>Gene Therapy</i> , 2000, 7, 458-463.	4.5	61
83	Xenotransplantation: is the risk of viral infection as great as we thought?. <i>Trends in Molecular Medicine</i> , 2000, 6, 199-208.	2.6	36
84	Rapid and sensitive detection of enhanced green fluorescent protein expression in paraffin sections by confocal laser scanning microscopy. <i>The Histochemical Journal</i> , 2000, 32, 99-103.	0.6	42
85	Modulation of Moloney Leukemia Virus Long Terminal Repeat Transcriptional Activity by the Murine CD4 Silencer in Retroviral Vectors. <i>Virology</i> , 2000, 276, 83-92.	2.4	10
86	Superantigen Expression Is Driven by Both Mouse Mammary Tumor Virus Long Terminal Repeat-Associated Promoters in Transgenic Mice. <i>Journal of Virology</i> , 2000, 74, 2900-2902.	3.4	6
87	Immunotherapy of a Viral Disease by in Vivo Production of Therapeutic Monoclonal Antibodies. <i>Human Gene Therapy</i> , 2000, 11, 1407-1415.	2.7	30
88	Phase I-study with encapsulated cells genetically modified to produce the ifosfamide activating cytochrome p 450 2B1 in patients with inoperable pancreatic carcinoma. <i>Gastroenterology</i> , 2000, 118, A522.	1.3	0
89	Development of Cellulose Sulfate-based Polyelectrolyte Complex Microcapsules for Medical Applications. <i>Annals of the New York Academy of Sciences</i> , 1999, 875, 46-63.	3.8	107
90	Characterization of a Human Cell Clone Expressing Cytochrome P450 for Safe Use in Human Somatic Cell Therapy. <i>Annals of the New York Academy of Sciences</i> , 1999, 880, 326-336.	3.8	8

#	ARTICLE	IF	CITATIONS
91	Injection of Encapsulated Cells Producing an Ifosfamide-Activating Cytochrome P450 for Targeted Chemotherapy to Pancreatic Tumors. <i>Annals of the New York Academy of Sciences</i> , 1999, 880, 337-351.	3.8	32
92	Intraarterial Instillation of Microencapsulated Cells in the Pancreatic Arteries in Pig. <i>Annals of the New York Academy of Sciences</i> , 1999, 880, 374-378.	3.8	18
93	Needle injection catheter delivery of the gene for an antibacterial agent inhibits neointimal formation. <i>Gene Therapy</i> , 1999, 6, 737-748.	4.5	42
94	Cell therapy using microencapsulated 293 cells transfected with a gene construct expressing CYP2B1, an ifosfamide converting enzyme, instilled intra-arterially in patients with advanced-stage pancreatic carcinoma: a phase I/II study. <i>Journal of Molecular Medicine</i> , 1999, 77, 393-398.	3.9	50
95	Proviral load determination of different feline immunodeficiency virus isolates using real-time polymerase chain reaction: Influence of mismatches on quantification. <i>Electrophoresis</i> , 1999, 20, 291-299.	2.4	172
96	Protection of MLV Vector Particles from Human Complement. <i>Biochemical and Biophysical Research Communications</i> , 1999, 264, 1-5.	2.1	14
97	Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450. <i>Gene Therapy</i> , 1998, 5, 1070-1078.	4.5	101
98	Effect of simian virus large T antigen expression on cell cycle control and apoptosis in rat pleural mesothelial cells exposed to DNA damaging agents. <i>Oncogene</i> , 1998, 16, 1041-1053.	5.9	26
99	Cell targeting by murine retroviral vectors. <i>Critical Reviews in Oncology/Hematology</i> , 1998, 28, 7-30.	4.4	21
100	Mapping of a mouse mammary tumor virus integration site by retroviral LTR- α arbitrary polymerase chain reaction. <i>Virus Research</i> , 1998, 54, 207-215.	2.2	4
101	Expression of Antimicrobial Peptides Has an Antitumour Effect in Human Cells. <i>Biochemical and Biophysical Research Communications</i> , 1998, 242, 608-612.	2.1	95
102	A Functional Eukaryotic Promoter Is Contained within the First Intron of the hGH-N Coding Region. <i>Biochemical and Biophysical Research Communications</i> , 1998, 247, 332-337.	2.1	9
103	Construction and Characterization of a Hybrid Mouse Mammary Tumor Virus/Murine Leukemia Virus-Based Retroviral Vector. <i>Journal of Virology</i> , 1998, 72, 1699-1703.	3.4	17
104	Intratumoral Injection of Encapsulated Cells Producing an Oxazaphosphorine Activating Cytochrome P450 for Targeted Chemotherapy. <i>Advances in Experimental Medicine and Biology</i> , 1998, 451, 97-106.	1.6	28
105	CrFK Feline Kidney Cells Produce an RD114-Like Endogenous Virus That Can Package Murine Leukemia Virus-Based Vectors. <i>Journal of Virology</i> , 1998, 72, 7685-7687.	3.4	27
106	Rapid identification of viable retrovirus-transduced cells using the green fluorescent protein as a marker. <i>Gene Therapy</i> , 1997, 4, 1256-1260.	4.5	52
107	Inducible expression of p21 WAF-1/CIP-1/SDI-1 from a promoter conversion retroviral vector. <i>Journal of Molecular Medicine</i> , 1997, 75, 820-828.	3.9	17
108	Development of retroviral vectors as safe, targeted gene delivery systems. <i>Journal of Molecular Medicine</i> , 1996, 74, 171-182.	3.9	34

#	ARTICLE	IF	CITATIONS
109	Identification of three human sequences with viral superantigen-specific primers. <i>Mammalian Genome</i> , 1995, 6, 339-344.	2.2	17
110	Retroviral vectors directed to predefined cell types for gene therapy. <i>Biologicals</i> , 1995, 23, 5-12.	1.4	11
111	Negative-acting factor and superantigen are separable activities of the mouse mammary tumor virus long terminal repeat.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995, 92, 2745-2749.	7.1	11
112	Virus vector design in gene therapy. <i>Trends in Molecular Medicine</i> , 1995, 1, 410-417.	2.6	50
113	Conditional expression of human TNF- α : A system for inducible cytotoxicity. <i>International Journal of Cancer</i> , 1994, 59, 103-107.	5.1	13
114	Negative regulatory element in the mammary specific whey acidic protein promoter. <i>Journal of Cellular Biochemistry</i> , 1994, 56, 245-261.	2.6	18
115	Endogenous superantigen expression controlled by a novel promoter in the MMTV long terminal repeat. <i>Nature</i> , 1993, 364, 154-158.	27.8	52
116	Targeting of Retroviral Vectors for Gene Therapy. <i>Human Gene Therapy</i> , 1993, 4, 129-141.	2.7	150
117	A modified procedure for replica plating of mammalian cells allowing selection of clones based on gene expression. <i>BioTechniques</i> , 1992, 12, 244-51.	1.8	8
118	A Mammary-Specific Promoter Directs Expression of Growth Hormone not only to the Mammary Gland, but also to Bergman Glia Cells in Transgenic Mice. <i>Molecular Endocrinology</i> , 1991, 5, 123-133.	3.7	83
119	naf, a trans-regulating negative-acting factor encoded within the mouse mammary tumor virus open reading frame region. <i>Journal of Virology</i> , 1990, 64, 6355-6359.	3.4	38
120	Construction and characterization of a packaging cell line for MMTV-based conditional retroviral vectors. <i>Biochemical and Biophysical Research Communications</i> , 1989, 159, 1191-1198.	2.1	24
121	Tumorigenic Conversion of in vivo Differentiation Competent Mammary Cells by Introduction and Expression of ras or mil(raf) but not myc. , 1989, , 199-210.		1
122	Expression of the oncogenes mil and ras abolishes the in vivo differentiation of mammary epithelial cells. <i>Carcinogenesis</i> , 1988, 9, 1849-1856.	2.8	20
123	Common Events in Mitogenic and Oncogenic Pathways. , 1988, , 109-121.		0
124	Current perspectives in the biology of mouse mammary tumour virus. <i>Virus Research</i> , 1987, 8, 81-102.	2.2	74
125	Mouse mammary tumor virus mediated transfer and expression of neomycin resistance to infected cultured cells. <i>Virology</i> , 1986, 155, 236-248.	2.4	35
126	The endogenous mouse mammary tumour virus locus Mtv-8 contains a defective envelope gene. <i>Virus Research</i> , 1986, 4, 377-389.	2.2	24

#	ARTICLE	IF	CITATIONS
127	Retroviral Vectors. , 0 , 35-60.		0